Drug intelligence / Profile preview

AMX160

Development stage
Preclinical
Lead developer
Arjuna Natural
Administration
Oral
01

Overview

AMX160 is a standardized botanical extract derived from the fresh fruit of Indian Gooseberry (*Phyllanthus emblica* L., also known as *Emblica officinalis*). Developed by Arjuna Natural, it is primarily investigated for the management of hypercholesterolemia and dyslipidemia. The extract is characterized by a high concentration of bioactive polyphenols and flavonoids. Its mechanism of action involves the inhibition of hepatic 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme in cholesterol biosynthesis, which leads to a reduction in total cholesterol, LDL cholesterol, and triglycerides. Additionally, AMX160 exhibits potent antioxidant properties that help attenuate lipid peroxidation. It is marketed under the brand name Tri-low as a nutraceutical ingredient for cardiovascular health and has been evaluated in clinical trials as a natural alternative or adjunct to conventional lipid-lowering therapies.

Brand names
Tri-low
Other names
Indian Gooseberry ExtractPhyllanthus emblica extractEmblica officinalis extractAmla extract
02

Targets

HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)

Beyond the preview

Go deeper on AMX160.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on AMX160.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call